Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease.
125I-Nerve growth factor (NGF) binding sites were analyzed by autoradiography in the striatum of 3 control subjects, 3 patients with Parkinson's disease and 3 patients with progressive supranuclear palsy. A high level of 125I-NGF binding was observed (0.3-0.4 fmol/mg of tissue equivalent) in the striatum and the nucleus basalis of Meynert of control patients. Pockets of lower 125I-NGF binding corresponding to acetylcholinesterase-poor striosomes were detected in the striatum of control subjects and patients with Parkinson's disease or progressive supranuclear palsy. When compared to controls, the density of 125I-NGF binding sites was reduced by 30% in the striatum of patients with progressive supranuclear palsy but not reduced in that of patients with Parkinson's disease. 125I-NGF binding was not significantly decreased in the nucleus basalis of Meynert in either diseases. Since NGF receptors are thought to be localized on cholinergic neurons in the striatum, the decrease in NGF binding is compatible with the loss of cholinergic neurons reported in the striatum from PSP patients.
Villares
J
J
INSERM U289, Hôpital de la Salpêtrière, Paris, France.
Strada
O
O
Faucheux
B
B
Javoy-Agid
F
F
Agid
Y
Y
Hirsch
E C
EC
D000368:Aged; D000369:Aged, 80 and over; D001345:Autoradiography; D001665:Binding Sites; D001667:Binding, Competitive; D002102:Cadaver; D003342:Corpus Striatum / Q000378:metabolism*; D006801:Humans; D009414:Nerve Growth Factors / Q000378:metabolism*; D010300:Parkinson Disease / Q000378:metabolism*; D013494:Supranuclear Palsy, Progressive / Q000378:metabolism*
D009414:Nerve Growth Factors